In the context of gene therapy and correction, CRISPR/Cas9 technology has also been explored for in vivo restoration of RPGR expression (the gene responsible for X-linked retinitis pigmentosa, XLRP) in animal models to treat a severe form of inherited retinal degeneration [22,95,178]. Here, RPGR is linked to retinal degeneration.